Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
- 28 May 2001
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 20 (24) , 3110-3115
Abstract
Recent discoveries have identified key molecular events in the pathogenesis of acute promyelocytic leukemia (APL), caused by chromosomal rearrangements of the transcription factor RAR (resulting in a fusion protein with the product of other cellular genes, such as PML). Oligomerization of RAR, through a self-association domain present in PML, imposes an altered interaction with transcriptional co-regulators (NCoR/SMRT). NCoR/SMRT are responsible for recruitment of histone deacetylases (HDACs), which is required for transcriptional repression of PML-RAR target genes, and for the transforming potential of the fusion protein. Oligomerization and altered recruitment of HDACs are also responsible for transformation by the fusion protein AML1-ETO, extending these mechanisms to other forms of acute myeloid leukemias (AMLs) and suggesting that HDAC is a common target for myeloid leukemias. Strikingly, AML1-ETO expression blocks retinoic acid (RA) signaling in hematopoietic cells, suggesting that interference with the RA pathway (genetically altered in APL) by HDAC recruitment may be a common theme in AMLs. Treatment of APLs with RA, and of other AMLs with RA plus HDAC inhibitors (HDACi), results in myeloid differentiation. Thus, activation of the RA signaling pathway and inhibition of HDAC activity might represent a general strategy for the differentiation treatment of myeloid leukemias.Keywords
This publication has 42 references indexed in Scilit:
- The language of covalent histone modificationsNature, 2000
- A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrestOncogene, 1999
- Coactivator and corepressor complexes in nuclear receptor functionCurrent Opinion in Genetics & Development, 1999
- Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APLNature Genetics, 1998
- Chronic myeloid leukemiaCurrent Opinion in Hematology, 1998
- A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human LeukemiaScience, 1997
- Transcriptional activation by recruitmentNature, 1997
- AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expressionNature Genetics, 1997
- Transcriptional Activation of the Human p21 Gene by Retinoic Acid ReceptorJournal of Biological Chemistry, 1996
- Does this have a familiar RING?Trends in Biochemical Sciences, 1996